Gossamer Bio Wins Big with $276 Million IPO
After struggling with IPO launches during the U.S. government shutdown, Gossamer Bio got on the market and raised $276 million, exceeding expectations.
After struggling with IPO launches during the U.S. government shutdown, Gossamer Bio got on the market and raised $276 million, exceeding expectations.
2018 was a record year for biotech initial public offerings (IPOs), but 2019 is off to a slow and rocky start because of the government shutdown.
About 400 U.S. Food and Drug Administration staffers returned to their posts from furlough, including some food inspectors and support professionals, Commissioner Scott Gottlieb said in a tweet.